- Home
- SILC vs CTOR Comparison
SILC vs CTOR Comparison
Compare SILC & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- CTOR
- Stock Information
- Founded
- SILC 1987
- CTOR 2021
- Country
- SILC Israel
- CTOR United States
- Employees
- SILC N/A
- CTOR N/A
- Industry
- SILC Computer Manufacturing
- CTOR
- Sector
- SILC Technology
- CTOR
- Exchange
- SILC Nasdaq
- CTOR NYSE
- Market Cap
- SILC 91.4M
- CTOR 89.9M
- IPO Year
- SILC 1994
- CTOR N/A
- Fundamental
- Price
- SILC $14.90
- CTOR $0.93
- Analyst Decision
- SILC Hold
- CTOR Strong Buy
- Analyst Count
- SILC 2
- CTOR 2
- Target Price
- SILC N/A
- CTOR $4.50
- AVG Volume (30 Days)
- SILC 26.2K
- CTOR 3.6M
- Earning Date
- SILC 05-01-2025
- CTOR 05-21-2025
- Dividend Yield
- SILC N/A
- CTOR N/A
- EPS Growth
- SILC N/A
- CTOR N/A
- EPS
- SILC N/A
- CTOR N/A
- Revenue
- SILC $58,114,000.00
- CTOR N/A
- Revenue This Year
- SILC $6.22
- CTOR N/A
- Revenue Next Year
- SILC $19.10
- CTOR N/A
- P/E Ratio
- SILC N/A
- CTOR N/A
- Revenue Growth
- SILC N/A
- CTOR N/A
- 52 Week Low
- SILC $11.35
- CTOR $0.55
- 52 Week High
- SILC $18.24
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- SILC 39.78
- CTOR N/A
- Support Level
- SILC $14.38
- CTOR N/A
- Resistance Level
- SILC $15.37
- CTOR N/A
- Average True Range (ATR)
- SILC 0.68
- CTOR 0.00
- MACD
- SILC 0.04
- CTOR 0.00
- Stochastic Oscillator
- SILC 17.87
- CTOR 0.00
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.